TD Private Client Wealth’s MoonLake Immunotherapeutics MLTX Stock Holding History

TD Private Client Wealth’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-17	Closed	-$122	–	1691
2025 Q3	$122	Buy	+17	New	+$886	﹤0.01%	1506
2025 Q2	–	Sell	-9	Closed	-$352	–	1472
2025 Q1	$352	Buy	+9	New	+$388	﹤0.01%	1354

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

TD Private Client Wealth's MLTX Position: Q4 2025 in Review

TD Private Client Wealth sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2025, closing a stake of 17 shares — an estimated $122 sold.

TD Private Client Wealth first reported a position in MLTX in Q1 2025 and held it in 2 quarters. The position peaked at $352 in Q1 2025. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

TD Private Client Wealth reported no remaining MoonLake Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
TD Private Client Wealth sold 17 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $122.
TD Private Client Wealth first reported a position in MoonLake Immunotherapeutics in Q1 2025 and held it in 2 quarters.
TD Private Client Wealth's MoonLake Immunotherapeutics position peaked at $352 in Q1 2025.
130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on TD Private Client Wealth's 13F filing for Q4 2025, filed 5 Feb 2026.